Impact of Physiologically Based Pharmacokinetic Models on Regulatory Reviews and Product Labels: Frequent Utilization in the Field of Oncology
Authors:
Open Access
- 11 January 2017
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 101 (5) , 597-602
Abstract
Physiologically based pharmacokinetic (PBPK) modeling can be used to predict drug pharmacokinetics in virtual populations using models that integrate understanding of physiological systems. PBPK models have been widely utilized for predicting pharmacokinetics in clinically untested scenarios during drug applications and regulatory reviews in recent years. Here, we provide a comprehensive review of the application of PBPK in new drug application (NDA) review documents from the US Food and Drug Administration (FDA) in the past 4 years.Keywords
This publication has 4 references indexed in Scilit:
- Physiologically based pharmacokinetic modeling in regulatory decision‐making at the European Medicines AgencyClinical Pharmacology & Therapeutics, 2016
- Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory AcceptanceCurrent Pharmacology Reports, 2016
- Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPKCPT: Pharmacometrics & Systems Pharmacology, 2015
- Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspectiveClinical Pharmacology & Therapeutics, 2015